# Axcelis Technologies Inc. (ACLS) — Financial Analysis

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ACLS/thesis · /stocks/ACLS/memo

## Financial Snapshot

---
title: "Step 04 — Financial Snapshot & Quality"
ticker: ACLS
company: Axcelis Technologies Inc.
source: coverage-next-full
date: 2026-05-27
---

### Step 04 — Financial Snapshot & Quality

#### Key Findings
**Net positive.** Axcelis's financial statements show high quality. GAAP net income and operating cash flow are directionally consistent. Gross margins are durable and have actually improved slightly through the revenue decline. There are no accounting red flags identified. SBC is modest (~$15–20M/year). The primary financial quality note is a growing inventory position ($282–329M) that is atypical for a company in revenue decline — this warrants monitoring but is characteristic of equipment manufacturers maintaining parts buffers.

#### Implications for Thesis and Valuation
- Earnings quality is high: minimal GAAP-to-cash conversion gap
- No material accounting concerns, no history of restatements
- Inventory build ($282M at FY2024 → $329M at FY2025) in a revenue downturn is a mild yellow flag — could signal demand visibility issues
- Balance sheet is fortress-like: ~$145M cash, ~$42M debt (leases only)

#### Objective
Assess accounting quality, identify any financial statement adjustments, and conduct an adversarial research sweep for material risks.

#### Narrative Analysis

##### Income Statement Quality

**Revenue Recognition**: Axcelis recognizes revenue when control of equipment transfers to the customer — typically upon installation/acceptance for systems. Aftermarket parts revenue is recognized at point of delivery; service revenue over the service period [Judgment based on industry standard practice]. No concerns identified.

**Non-GAAP Adjustments**: Axcelis reports both GAAP and non-GAAP EPS. Non-GAAP adjusts for SBC, amortization, and certain other items. The gap is modest:
- FY2025 GAAP EPS: ~$3.80 | Non-GAAP EPS: ~$4.39 [S1]
- The ~15% non-GAAP adjustment is within normal range for technology manufacturers

**SBC Expense**: Stock-based compensation is estimated at ~$15–20M annually (moderate; ~2% of revenue at peak) [Estimate based on cash flow data]. This is a real economic cost but not distortive.

**Gross Margin Durability**: The most impressive financial quality signal is gross margin stability through a -26% revenue decline:
| Year | Revenue | Gross Profit | Gross Margin |
|------|---------|-------------|-------------|
| FY2021 | $662M | $286M | 43.2% |
| FY2022 | $920M | $402M | 43.7% |
| FY2023 | $1,131M | $491M | 43.4% |
| FY2024 | $1,018M | $455M | 44.7% |
| FY2025 | $839M | $377M | 44.9% |

Gross margin actually expanded 1.5pp from FY2023 peak to FY2025 trough despite $292M less revenue. This is extraordinary pricing discipline — indicative of a business with real product differentiation and non-commodity pricing power [S1].

##### Balance Sheet Quality

**Cash**: $145M at FY2025 year-end; $124M at FY2024. Cash decline is explained by the aggressive buyback program ($126M in FY2025) [S2].

**Inventory**: The most notable item. Inventory grew from $242M (FY2022) → $307M (FY2023) → $282M (FY2024) → $329M (FY2025 StockAnalysis) despite revenue declining from $1.13B to $839M. Inventory-to-revenue ratio rose from ~21% at peak to ~39% at trough. This is elevated but not alarming for equipment manufacturers:
- Equipment manufacturers maintain WIP for standard build-cycles
- Aftermarket parts inventory is large and grows with installed base
- Risk: if demand recovery is weaker than expected, inventory impairment charges are possible

**Accounts Receivable**: $203M (FY2024) → $168M (FY2025). AR declining with revenue — appropriate DSO management. No concern.

**Debt**: Only ~$42M in lease obligations (operating + finance). Zero financial debt outstanding. Net cash position [S2].

##### Cash Flow Quality

**OCF vs. Net Income Reconciliation**
| Year | Net Income | OCF | Difference | Quality Signal |
|------|-----------|-----|-----------|---------------|
| FY2021 | ~$99M | $150M | +$51M | Positive (working capital benefit) |
| FY2022 | $183M | $216M | +$33M | Good |
| FY2023 | $246M | $157M | -$89M | Inventory/WC build (explains gap) |
| FY2024 | $201M | $141M | -$60M | Continued WC drag |
| FY2025 | $120M | $118M | -$2M | Essentially flat; WC neutral |

OCF < Net Income in FY2023–2024 due to working capital build (inventory + AR growing with the boom). In FY2025, OCF and Net Income converged — working capital is no longer a drag [S2]. This is actually a positive signal: the working capital cycle is normalizing.

**Free Cash Flow**
| Year | FCF | Margin |
|------|-----|--------|
| FY2021 | $141M | 21.3% |
| FY2022 | $205M | 22.3% |
| FY2023 | $136M | 12.0% |
| FY2024 | $129M | 12.7% |
| FY2025 | $107M | 12.8% |

FCF margin compression from peak is explained by the working capital cycle described above. At $107M FCF on $839M revenue, FCF conversion is ~89% of GAAP net income — solid [S2].

---

#### Adversarial Research Sweep

**Research objective**: Identify short-seller reports, investor lawsuits, regulatory investigations, accounting allegations, channel-stuffing concerns, or other adversarial narratives.

##### Short Interest
Short interest is elevated at ~23.6% of float (~4.99M shares) as of May 2026 [S3]. The bear thesis is built on:
1. SiC equipment "supercycle" peaked in 2023; the correction will be deeper/longer than bulls expect
2. China export controls could remove 30–40% of revenue from addressable market
3. EV demand growth has disappointed, invalidating the SiC demand thesis
4. Veeco merger risk: China SAMR could block it or extract concessions

No formal short-seller research reports identified (no Hindenburg, Muddy Waters, etc.) [S3].

##### Legal / Regulatory
No material litigation identified. Veeco merger is subject to standard regulatory review [S4].

##### Management Track Record
No restatements, SEC investigations, or accounting irregularities identified in the 2020–2026 period. CEO Low joined Axcelis in 2016 and was promoted through technical and operational roles, becoming CEO in 2023 — an internal promotion with continuity [S4].

##### China Export Controls
U.S. Commerce Department implemented new ECCN classifications for certain 300mm ion implanters in December 2024. Some Chinese customers were added to the Entity List [S3][S4]. Management stated the company can currently ship to "substantially all" Chinese customers with appropriate licenses. This is a material ongoing risk but not a current crisis.

##### No Adverse Findings
**No accounting manipulation, restatement history, management fraud, or material litigation identified.** The elevated short interest represents a legitimate cyclical/macro bearish argument rather than fundamental integrity concerns.

#### Assumption Register Updates
- Inventory-to-revenue elevated at ~39%; flagged for monitoring but not a red flag

#### Tables and Calculations

##### Key Financial Metrics Summary
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|--------|--------|
| Revenue | $662M | $920M | $1,131M | $1,018M | $839M |
| Gross Margin | 43.2% | 43.7% | 43.4% | 44.7% | 44.9% |
| Op. Margin | 19.2% | 23.1% | 23.5% | 20.7% | 14.2% |
| Net Margin | 14.9% | 19.9% | 21.8% | 19.7% | 14.3% |
| FCF Margin | 21.3% | 22.3% | 12.0% | 12.7% | 12.8% |
| Inv/Revenue | 29.4% | 26.3% | 27.1% | 27.7% | 39.2% |
| Net Cash | $247M | $140M | $122M | $80M | $103M |

##### Adversarial Sweep Summary
| Risk Category | Finding | Severity |
|---------------|---------|---------|
| Accounting / Restatement | None identified | None |
| Management Integrity | None identified | None |
| Material Litigation | None identified | None |
| Short Seller Reports | None identified (formal reports) | None |
| China Export Controls | Material risk; ongoing monitoring needed | Medium |
| Inventory Build | Elevated; watch for impairment | Low–Medium |

#### Open Questions and Data Gaps
1. Detailed inventory breakdown (raw materials / WIP / finished goods) — would clarify impairment risk
2. Exact SBC dollar amount — estimated ~$15–20M; needs 10-K confirmation

#### Source Index
| Source Tag | Document or URL | Section | Date | Notes |
|------------|----------------|---------|------|-------|
| [S1] | StockAnalysis.com/stocks/acls/financials | Annual IS | 2026-05-27 | Revenue, GP, margins FY2021–FY2025 |
| [S2] | StockAnalysis.com/stocks/acls/financials/cash-flow | Annual CF | 2026-05-27 | OCF, FCF, buybacks FY2021–FY2025 |
| [S3] | MarketBeat / Benzinga short interest; web search | Short interest / bearish | 2026-05-27 | 23.6% float short; bear thesis |
| [S4] | Web search: ACLS management, regulatory, legal | General | 2026-05-27 | No restatements; China export controls; CEO background |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ACLS/fundamental

## Navigation

- Overview: /stocks/ACLS
- Financials (this page): /stocks/ACLS/financials
- Thesis: /stocks/ACLS/thesis
- Investment Memo: /stocks/ACLS/memo
- Coverage universe: /stocks